1 2 3 4 5 6 7 9 17 24 32

SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer

  • Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population.
  • Phase 1/2 study is evaluating SOT102, a Claudin 18.2 antibody-drug conjugate, for treatment of gastric and pancreatic cancers.

SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.


SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences

  • SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumors.
  • Preclinical efficacy and tolerability studies of SOT106 show promising results across multiple solid tumor indications and a beneficial therapeutic index.
  • SOTIO is actively exploring additional tumor targets to expand the collaboration with LegoChem Biosciences to up to five ADC programs.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that it has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB, KOSDAQ: 141080) for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications.